Literature DB >> 10628770

CD4+CD25+ cells regulate CD8 cell anergy in neonatal tolerant mice.

Q Gao1, T M Rouse, K Kazmerzak, E H Field.   

Abstract

BACKGROUND: Injection of neonatal BALB/c mice with semi-allogeneic splenocytes leads to antigen-specific tolerance lasting into adulthood. Tolerant mice accept A/J skin grafts and fail to generate CD8 cytotoxic T lymphocyte (CTL) activity against A/J targets. Anergic CD8 T cells are present in tolerant mice, and CD4 regulatory cells function to maintain CD8 cell anergy.
METHODS: Neonatal BALB/c mice were injected with 108 live CAF, splenocytes, and mice were deemed tolerant by accepting A/J grafts over 40 days. CD8 cell proliferation was measured by in vitro incorporation of bromodeoxyuridine coupled with fluorescence-activated cell sorter analysis. Alloantigen-specific cytotoxicity was tested using 51Cr release assays of A/J or third-party targets.
RESULTS: We demonstrate that A/J-specific anergic CD8 cells are present in neonatal primed mice that develop tolerance but not in neonatal primed mice that reject A/J skin grafts. Anergic CD8 cells show decreased proliferation and no CTL activity against A/J targets. Addition of interleukin-2 (IL-2) to unfractionated cultures fails to restore CTL activity against A/J targets. However, addition of IL-2 to CD4-depleted cultures restores A/J-specific CD8 CTL activity. Removal of CD4+/CD25+ cells, but not CD4+/CD25- cells, also restores CD8 CTL activity against A/J in the presence, but not the absence, of IL-2. Moreover, when added back into cultures, purified CD4+/CD25+ cells from tolerant mice inhibit the generation of CD8 CTL against A/J targets.
CONCLUSION: These data indicate that CD8 anergy is associated with the state of tolerance, and that CD4+CD25+ cells from tolerant mice function to maintain A/J-specific CD8 cell anergy in vitro.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10628770     DOI: 10.1097/00007890-199912270-00013

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

1.  Th2 alloimmunity counteracts Th17-type response in the neonatal establishment of lymphoid chimerism.

Authors:  Isabelle Debock; Véronique Flamand
Journal:  Chimerism       Date:  2011 Oct-Dec

2.  Natural Tregs, CD4+CD25+ inhibitory hybridomas, and their cell contact dependent suppression.

Authors:  Elizabeth H Field; Katarina Kulhankova; Mohamed E Nasr
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

3.  Expansion of regulatory CD8+ CD25+ T cells after neonatal alloimmunization.

Authors:  B Adams; A Dubois; S Delbauve; I Debock; F Lhommé; M Goldman; V Flamand
Journal:  Clin Exp Immunol       Date:  2010-12-22       Impact factor: 4.330

4.  Susceptibility of neonatal T cells and adult thymocytes to peripheral tolerance to allogeneic stimuli.

Authors:  Fábio B do Canto; Celso Lima Junior; Ivan A Teixeira; Maria Bellio; Alberto Nóbrega; Rita Fucs
Journal:  Immunology       Date:  2008-05-03       Impact factor: 7.397

5.  Specific ablation of CD4+ T-cells promotes heart regeneration in juvenile mice.

Authors:  Jiatao Li; Cai Liang; Kevin Y Yang; Xiuzhen Huang; Mao Ying Han; Xisheng Li; Vicken W Chan; Kathleen S Chan; Di Liu; Zhan-Peng Huang; Bin Zhou; Kathy O Lui
Journal:  Theranostics       Date:  2020-06-29       Impact factor: 11.556

6.  Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Petra Hoffmann; Joerg Ermann; Matthias Edinger; C Garrison Fathman; Samuel Strober
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

Review 7.  The potential of human regulatory T cells generated ex vivo as a treatment for lupus and other chronic inflammatory diseases.

Authors:  David A Horwitz; J Dixon Gray; Song Guo Zheng
Journal:  Arthritis Res       Date:  2002-03-12

Review 8.  Unbalanced Neonatal CD4(+) T-Cell Immunity.

Authors:  Isabelle Debock; Véronique Flamand
Journal:  Front Immunol       Date:  2014-08-27       Impact factor: 7.561

Review 9.  Transplant Tolerance Induction in Newborn Infants: Mechanisms, Advantages, and Potential Strategies.

Authors:  Hua Pan; Aram Gazarian; Jean-Michel Dubernard; Alexandre Belot; Marie-Cécile Michallet; Mauricette Michallet
Journal:  Front Immunol       Date:  2016-04-07       Impact factor: 7.561

10.  Inflammation-Induced Adverse Pregnancy and Neonatal Outcomes Can Be Improved by the Immunomodulatory Peptide Exendin-4.

Authors:  Valeria Garcia-Flores; Roberto Romero; Derek Miller; Yi Xu; Bogdan Done; Chharitha Veerapaneni; Yaozhu Leng; Marcia Arenas-Hernandez; Nabila Khan; Bogdan Panaitescu; Sonia S Hassan; Luis Marat Alvarez-Salas; Nardhy Gomez-Lopez
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.